In the United States, 50,000-60,000 new cases of Parkinson’s Disease are diagnosed each year, adding to the one million people who currently have PD. Parkinson’s disease is a neurodegenerative brain disorder that progresses slowly in most people.
Normally, there are brain cells (neurons) in the human brain that produce dopamine. Dopamine is a chemical that relays messages between the parts of the brain to control movements of the human body. Dopamine helps humans to have smooth coordinated muscle movements. When approximately 60 to 80% of the dopamine-producing cells are damaged, and do not produce enough dopamine, the motor symptoms of Parkinson’s disease appear. This process of impairment of brain cells is called neurodegeneration.
Below you will see studies on cannabis as a treatment option for Parkinson’s Disease. Please share the truth about the natural CURE ~ Cherry Girl
The Endocannabinoid System in Parkinson’s Disease
The evidence that endoCANNABINOIDS play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in endoCANNABINOID signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the endoCANNABINOID system as symptomatic and neuroprotective therapeutic strategies for Parkinson’s Disease.
Cannabinoids and Parkinson’s Disease
Cannabinoid-based medicines in PD have been still scarcely studied at the clinical level despite the existence of solid and promising preclinical evidence. Considering the relevance of these preclinical data, the need for finding treatments for motor symptoms that may be alternative to classic dopaminergic replacement therapy, and the lack of efficient neuroprotective strategies in PD, we believe it is of major interest to develop further studies that allow the promising expectations generated for these molecules to progress from the present preclinical evidence towards a real clinical application.
A Role For Endocannabinoids In the Generation of Parkinsonism and Levodopa-Induced Dyskinesia in MPTP-Lesioned Non-Human Primate Models of Parkinson’s Disease
Endocannabinoids and cannabinoid CB1 receptors play a role in Parkinson’s Disease. Levodopa (Big Pharma’s PD treatment ) causes LID (Levodopa-induced dyskinesia), a side effect. Rimonabant (THC) did not elicit dyskinesia. Co-administration of levodopa and rimonabant (THC) resulted in significantly less dyskinesia than levodopa alone, without significantly affecting the anti-parkinsonian action of levodopa. These data suggest that enhanced endocannabinoid signaling may be involved in the pathophysiology of both parkinsonism and LID.
Cannabinoids Provide Neuroprotection Against 6-Hydroxydopamine Toxicity in Vivo and in Vitro: Relevance to Parkinson’s Disease
2005: In summary, our results support the view of a potential neuroprotective action of cannabinoids against the in vivo and in vitro toxicity of 6-hydroxydopamine, which might be relevant for Parkinson’s Disease (PD). Our data indicated that these neuroprotective effects might be due, among others, to the antioxidant properties of certain plant-derived cannabinoids, or exerted through the capability of cannabinoid agonists to modulate glial function, or produced by a combination of both mechanisms.
An Overview of Parkinson’s Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments
2006: “Despite the many recent advances in the symptomatic treatment of PD, there is still no realistic prospect for a cure. In recent years, new data support the idea of a relevant role for the cannabinoid system in PD. Collectively, all these evidence support that the management of the cannabinoid system might represent a new approach to the treatment of PD.”—In other words: Cannabinoids from cannabis are a realistic prospect for THe Cure, thanks to cannabinoid receptors and the endocannabinoid system.
Evaluation of the Neuroprotective Effect of Cannabinoids in A Rat Model of Parkinson’s Disease: Importance of Antioxidant and Cannabinoid Receptor-Independent Properties
2007: “We have recently demonstrated that two plant-derived cannabinoids, Delta9-tetrahydrocannabinol and cannabidiol (CBD), are neuroprotective in an animal model of Parkinson’s disease (PD), presumably because of their antioxidant properties.Our results indicate that those cannabinoids having antioxidant cannabinoid receptor-independent properties provide neuroprotection against the progressive degeneration of nigrostriatal dopaminergic neurons occurring in PD.
Therapeutic Effects of Delta9-THC and Modafinil in A Marmoset Parkinson Model
This science is about the therapeutic effects of THC and modafinil in a marmoset Parkinson model. It states: “It can be concluded that both compounds have therapeutic values and could supplement existing therapies for PD.”—-In other words: cannabis has medical value.
Cannabidiol For the Treatment of Psychosis in Parkinson’s Disease
The management of psychosis in Parkinson’s disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention.Previously an antipsychotic and neuroprotective effect of Cannabidiol (CBD) has been suggested.Therefore, the aim of the present study was to directly evaluate for the first time, the efficacy, tolerability and safety of CBD on PD patients with psychotic symptoms.No adverse effect was observed during the treatment. These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.
Homeostatic Changes of the Endocannabinoid System in Parkinson’s Disease
We provide a brief survey of the evidence that the endoCANNABINOID SYSTEM changes in both animal models of, and patients suffering from, Parkinson’s Disease. A striking convergence of findings is observed between both rodent and primate models and PD patients, indicating that the eCB system undergoes dynamic, adaptive changes, aimed at restoring an apparent homeostasis within the basal ganglia network.”—In other words: The endocannabinoid system uses cannabinoids to restore homeostasis.
Regional Changes in Type 1 Cannabinoid Receptor Availability in Parkinson’s Disease in Vivo
The type 1 cannabinoid receptor (CB1) is a crucial modulator of synaptic transmission in brain and has been proposed as a potential therapeutic target in Parkinson’s disease (PD), especially for treatment of levodopa-induced dyskinesias (LID). These data demonstrate regional changes in CB1 availability in PD in vivo, but do not support a role for dysregulation of CB1 levels in the pathogenesis of LID.”—In other words: CB1 disregulation is responsible for Parkinson’s, but not LID, the side-effect of Levodopa, the current treatment for Parkinson’s.
Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated With Parkinson’s Disease
This review aims to highlight several reported properties of cannabinoids that could be used to inhibit the adverse neuroinflammatory processes contributing to Parkinson’s disease and possibly other neurodegenerative disorders. These include anti-oxidant properties of phytocannabinoids… further pharmacological studies are needed to allow rational design of new cannabinoid-based drugs lacking detrimental in vivo effects. (Comment: “Isn’t it strange how Big Pharma considers euphoria and appetite stimulation as unacceptable “detrimental effects” of cannabinoids, but “sudden death, violent outbursts, and/or suicidal tendancies” are acceptable side-effects for Big Pharma products?”DW)
Symptom-Relieving and Neuroprotective Effects of the Phytocannabinoid Δ⁹-THCV in Animal Models of Parkinson’s Disease
Previous findings have indicated that a cannabinoid, such as Δ(9)-THCV, which has antioxidant properties and the ability to activate CB(2) receptors but to block CB(1) , might be a promising therapy for alleviating symptoms and delaying neurodegeneration in Parkinson’s disease (PD). IMPLICATIONS: Given its antioxidant properties and its ability to activate CB(2) but to block CB(1) receptors, Δ(9)-THCV has a promising pharmacological profile for delaying disease progression in PD and also for ameliorating parkinsonian symptoms.
- Prevention and Treatment of Alzheimer’s Disease With Cannabis (cherrygurl28.com)
- Regenerative Medicine:Cannabis and Stem Cells (cherrygurl28.wordpress.com)
- Regenerative Medicine:Cannabis and Stem Cells (cherrygurl28.com)
- A Natural Choice For Pain Management (cherrygurl28.com)
- The Human Body and Cannabis: Understanding Our Endocannabinoid System (cherrygurl28.com)